Glaukos (GKOS) Scheduled to Post Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) is scheduled to be announcing its earnings results after the market closes on Wednesday, July 31st. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Glaukos has set its FY 2024 guidance at EPS.Parties interested in registering for the company’s earnings conference call can do so using this link.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. Glaukos’s quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Stock Performance

GKOS stock opened at $119.69 on Tuesday. The company has a market cap of $6.03 billion, a P/E ratio of -41.56 and a beta of 1.06. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.68. Glaukos has a 1 year low of $59.22 and a 1 year high of $126.96. The stock’s fifty day moving average price is $116.09 and its 200-day moving average price is $102.31.

Analysts Set New Price Targets

A number of research firms have issued reports on GKOS. Morgan Stanley boosted their price target on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC upped their target price on shares of Glaukos from $108.00 to $113.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Citigroup cut shares of Glaukos from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $130.00 to $132.00 in a research note on Wednesday, July 10th. JPMorgan Chase & Co. upped their price objective on Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Finally, StockNews.com downgraded Glaukos from a “hold” rating to a “sell” rating in a research report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $120.64.

Insider Buying and Selling at Glaukos

In related news, CFO Alex R. Thurman sold 353 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $110.51, for a total transaction of $39,010.03. Following the completion of the transaction, the chief financial officer now owns 51,647 shares in the company, valued at $5,707,509.97. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Glaukos news, COO Joseph E. Gilliam sold 2,250 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $121.39, for a total transaction of $273,127.50. Following the completion of the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $12,362,964.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alex R. Thurman sold 353 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $110.51, for a total value of $39,010.03. Following the sale, the chief financial officer now directly owns 51,647 shares in the company, valued at $5,707,509.97. The disclosure for this sale can be found here. Insiders sold a total of 21,444 shares of company stock valued at $2,411,171 in the last three months. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.